BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 7903199)

  • 1. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
    Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymic programs of rat bone marrow and the impact of acivicin and tiazofurin.
    Prajda N; Natsumeda Y; Ikegami T; Reardon MA; Szondy S; Hashimoto Y; Emrani J; Weber G
    Biochem Pharmacol; 1988 Mar; 37(5):875-80. PubMed ID: 3345200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted and non-targeted actions of anti-cancer drugs.
    Weber G; Prajda N
    Adv Enzyme Regul; 1994; 34():71-89. PubMed ID: 7942286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
    Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
    Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
    Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
    Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
    Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
    Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
    Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
    Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
    Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiazofurin decreases Ras-GTP complex in K562 cells.
    Hata Y; Natsumeda Y; Weber G
    Oncol Res; 1993; 5(4-5):161-4. PubMed ID: 8305741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
    Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
    Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purine metabolism of human glioblastoma in vivo.
    Pillwein K; Chiba P; Knoflach A; Czermak B; Schuchter K; Gersdorf E; Ausserer B; Murr C; Goebl R; Stockhammer G
    Cancer Res; 1990 Mar; 50(5):1576-9. PubMed ID: 2154328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
    Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
    Sokoloski JA; Sartorelli AC
    Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.
    Weber G; Natsumeda Y; Lui MS; Faderan MA; Liepnieks JJ; Elliott WL
    Adv Enzyme Regul; 1984; 22():69-93. PubMed ID: 6206692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells.
    Natsumeda Y; Ikegami T; Olah E; Weber G
    Cancer Res; 1989 Jan; 49(1):88-92. PubMed ID: 2461800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.